An innovative new pill could soon offer a new and affordable weight management treatment, following a successful clinical ...

A novel monoclonal antibody, developed by US researchers, has shown promise against malaria infection in an early clinical ...

Natera (NTRA) announced results from the randomized, double-blind, phase 3 IMvigor011 clinical trial in muscle-invasive bladder cancer. The ...

(NASDAQ: NTRA), a global leader in cell-free DNA and precision medicine, today announced results from the randomized, double-blind, phase 3 IMvigor011 clinical trial in muscle-invasive bladder cancer ...

The DUO-O trial showed significant improvement in progression-free survival with Imfinzi, Avastin, and Lynparza, but no ...

A Taiwan trial found a plant-based serum boosted hair density by 25% in eight weeks using growth factors and natural vesicles ...

The MANEUVER trial was a global, randomized, double-blind, placebo-controlled study evaluating pimicotinib in unresectable TGCT patients. Pimicotinib shows promising long-term efficacy in treating ...

Malaria remains one of the leading causes of death among children in sub-Saharan Africa, claiming more than 600,000 lives ...

Crawford, a medical oncologist at Duke Cancer Center and Duke Cancer Center Thoracic Clinic in Durham, North Carolina, ...

Provides clarity on the aspects to incorporate Company to address them and resubmit revised protocol MADRID, Spain and CAMBRIDGE, Mass., Oct.

About PYRUKYND® (mitapivat) U.S. INDICATION PYRUKYND is a pyruvate kinase activator indicated for the treatment of hemolytic anemia in adults with pyruvate kinase (PK) deficiency.

Clarametyx has concluded subject enrolment in its Phase Ib/IIa study of CMTX-101, an immune-enhancing antibody therapy being ...